German biotech startup Cambrium raises €8m in Seed to Commercialize New Class of Performance Molecules

Cambrium‘s mission is to trigger the next wave of material innovation by harnessing biology’s molecular building blocks. The startup believes that the ability to align economic and environmental incentives makes biology the most important manufacturing technology of the 21st century. Using its molecular design technology, it creates novel material building blocks with previously inaccessible functionalities. Its molecules enable innovators to create products that are better for people, and the planet. Here are details of Cambrium’s latest funding round :

🚀 Launch

2020

🏭 Industry

Biotechnology

🧠Management

Mitchell Duffy (Co-founder & CEO), Charlie Cotton (Co-founder & CSO), Daria Mühlebach (Head of Finance & Operations), Lucile Bonnin (Head of R&D), Ruben Von Krannichfeldt (Head of Business Development), Pierre Salvy (Head of Engineering)

💸 Funding & Investors

INVESTMENT (October 2023)€8 million (Seed)
INVESTORS (October 2023)led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital.

🎯 Funding purpose

Commercial growth; Industry expansion

🌐 Country HQ

Germany (Berlin)

Leave a Reply

Your email address will not be published.